Goals and Analytical Methodologies for Protein Disposition Studies
暂无分享,去创建一个
[1] P. Familletti,et al. Structural characterization of human interferon γ Heterogeneity of the carboxyl terminus , 1987 .
[2] R. Kurzrock,et al. Pharmacokinetics, Single-Dose Tolerance, and Biological Activity of Recombinant γ-lnterferon in Cancer Patients , 1985 .
[3] J. Villafranca,et al. Current research in protein chemistry : techniques, structure, and function , 1990 .
[4] K. Kohnert,et al. Radioiodination of peptide hormones and immunoglobulin preparations: comparison of the chloramine T and iodogen method. , 2009, Experimental and clinical endocrinology.
[5] P. Ghezzi,et al. Recombinant tumor necrosis factor depresses cytochrome P450-dependent microsomal drug metabolism in mice. , 1986, Biochemical and biophysical research communications.
[6] G. Ooi. Insulin-like growth factor-binding proteins (IGFBPs): more than just 1, 2, 3 , 1990, Molecular and Cellular Endocrinology.
[7] A. Jones,et al. Hepatic sequestration and biliary secretion of epidermal growth factor: evidence for a high-capacity uptake system. , 1983, Proceedings of the National Academy of Sciences of the United States of America.
[8] B. Desbuquois,et al. Receptor-Mediated Internalisation of Insulin, Glucagon and Growth Hormone in Intact Rat Liver. A Biochemical Study , 1980 .
[9] J. Figueiredo,et al. Renal filtration, transport, and metabolism of low-molecular-weight proteins: a review. , 1979, Kidney international.
[10] J. Ketelslegers,et al. Different effects of intermittent and continuous growth hormone (GH) administration on serum somatomedin-C/insulin-like growth factor I and liver GH receptors in hypophysectomized rats. , 1988, Endocrinology.
[11] E. Rinderknecht,et al. Natural human interferon-gamma. Complete amino acid sequence and determination of sites of glycosylation. , 1984, The Journal of biological chemistry.
[12] L. Frohman,et al. Concomitant association between high plasma levels of growth hormone and low hepatic mixed-function oxidase activity in the young rat. , 1974, Journal of Pharmacology and Experimental Therapeutics.
[13] T. Iga,et al. Kinetic analysis of the elimination process of human epidermal growth factor (hEGF) in rats. , 1989, Biochemical pharmacology.
[14] M. Fukuda,et al. Survival of recombinant erythropoietin in the circulation: the role of carbohydrates. , 1989 .
[15] A. B. Jansen. Total radioactivity half-lives. , 1979, Drug metabolism and disposition: the biological fate of chemicals.
[16] E. Arquilla,et al. Effect of Isologous and Autologous Insulin Antibodies on In Vivo Bioavailability and Metabolic Fate of Immune-Complexed Insulin in Lou/M Rats , 1989, Diabetes.
[17] Norman A. Mazer,et al. Pharmacokinetic and pharmacodynamic aspects of polypeptide delivery , 1990 .
[18] B. Finkle,et al. The Influence of Recombinant DNA-Derived Human and Murine Gamma Interferons on Mouse Hepatic Drug Metabolism , 1986 .
[19] F. Komada,et al. Fate of porcine and human insulin at the subcutaneous injection site. II. In vitro degradation of insulins in the subcutaneous tissue of the rat. , 1985, Journal of pharmacobio-dynamics.
[20] R. Quirion. Bioassays in modern peptide research , 1982, Peptides.
[21] Gerhard Giebisch,et al. The Kidney: Physiology and Pathophysiology , 1992 .
[22] J. Mordenti,et al. The Role of Pharmacokinetics and Pharmacodynamics in the Development of Therapeutic Proteins , 1991 .
[23] R. Fernandez-Botran,et al. A soluble, high-affinity, interleukin-4-binding protein is present in the biological fluids of mice. , 1990, Proceedings of the National Academy of Sciences of the United States of America.
[24] A. Billiau. The biology of the interferon system 1984: edited by H. Kirchner and H. Schellekens, Elsevier Science Publishers, 1985. Dfl. 300.00 (xv + 654 pages) ISBN 0 444 80661 X , 1985 .
[25] W. Ward,et al. Uptake and intracellular fate of [14C]sucrose-insulin in perfused rat livers. , 1988, The American journal of physiology.
[26] M. Waters,et al. Regulation of growth hormone (GH) bioactivity by a recombinant human GH-binding protein. , 1990, Endocrinology.
[27] B. Beutler,et al. Cachectin/tumor necrosis factor: production, distribution, and metabolic fate in vivo. , 1985, Journal of immunology.
[28] B. Finkle,et al. Effect of murine gamma-interferon on the mouse liver and its drug-metabolizing enzymes: comparison with human hybrid alpha-interferon. , 1985, Journal of interferon research.
[29] T. Blundell,et al. Chemistry, structure and function of insulin and related hormones , 1980, FEBS letters.
[30] J. Parsons,et al. EVIDENCE THAT PROTEASE INHIBITORS REDUCE THE DEGRADATION OF PARATHYROID HORMONE AND CALCITONIN INJECTED SUBCUTANEOUSLY , 1979, British journal of pharmacology.
[31] T. Elsasser,et al. Validation of a heterologous radioimmunoassay for insulin-like growth factor-I in bovine serum. , 1988, The Journal of endocrinology.
[32] C. Hales,et al. RADIOIMMUNOASSAY MAY OVERESTIMATE INSULIN IN NON‐INSULIN‐DEPENDENT DIABETICS , 1990, Clinical endocrinology.
[33] B. Sobel,et al. Biochemical determinants of clearance of tissue-type plasminogen activator from the circulation. , 1988, Circulation.
[34] B. Keyt,et al. Circulatory metabolism of recombinant tissue-type plasminogen activator in monkeys and rabbits , 1988 .
[35] A. Kerlavage. The Use of HPLC in receptor biochemistry , 1989 .
[36] G. Firestone,et al. Immunoprecipitation of proteins. , 1990, Methods in enzymology.
[37] F. Lederer,et al. Characterization of insulin degradation products generated in liver endosomes: In vivo and in vitro studies , 1990, Molecular and Cellular Endocrinology.
[38] M. Shaw,et al. A second, lower affinity growth hormone-binding protein in human plasma. , 1990, The Journal of clinical endocrinology and metabolism.
[39] J. Henkin,et al. Enhanced lytic efficacy of multiple bolus injections of tissue plasminogen activator in dogs. , 1990, Thrombosis research.
[40] L. Creighton,et al. Investigation by HPLC of the Catabolism of Recombinant Tissue Plasminogen Activator in the Rat , 1988, Thrombosis and Haemostasis.
[41] M. Huang,et al. Effects of three recombinant human leukocyte interferons on drug metabolism in mice. , 1982, Drug metabolism and disposition: the biological fate of chemicals.
[42] R. Wills. Clinical Pharmacokinetics of Interferons , 1990, Clinical pharmacokinetics.
[43] T. Blaschke,et al. Interferon reduces hepatic drug metabolism in vivo in mice. , 1985, Drug metabolism and disposition: the biological fate of chemicals.
[44] S. Nielsen,et al. Luminal uptake of insulin in renal proximal tubules. , 1988, Contributions to nephrology.
[45] R. D. Wade. ELISA and other solid phase immunoassays: Edited by D M Kemeny and S J Challacombe. pp 367. John Wiley, Chichester, UK. 1988. $47.95 ISBN 0-471-90982-3 , 1989 .
[46] T. Waldmann,et al. The role of the kidney in the metabolism of plasma proteins. , 1974, Nephron.
[47] M. Mohler,et al. Biodisposition and catabolism of tissue-type plasminogen activator in rats and rabbits , 1988 .
[48] J. Jansson,et al. Pulsatile intravenous growth hormone (GH) infusion to hypophysectomized rats increases insulin-like growth factor I messenger ribonucleic acid in skeletal tissues more effectively than continuous GH infusion. , 1988, Endocrinology.
[49] T. Arakawa,et al. Role of polycationic C-terminal portion in the structure and activity of recombinant human interferon-gamma. , 1986, The Journal of biological chemistry.
[50] V. Jörgens,et al. Absorption Kinetics and Biologic Effects of Subcutaneously Injected Insulin Preparations , 1982, Diabetes Care.
[51] B. Dunbar,et al. [51] Protein blotting and immunodetection , 1990 .
[52] A. Tsuji,et al. Application of HPLC in Disposition Study of A14-125I-Labeled Insulin in Mice , 1990, Diabetes.
[53] F. Carone,et al. Renal tubular processing of small peptide hormones. , 1982, The Journal of laboratory and clinical medicine.
[54] L. Cecco,et al. Luteinizing hormone determinations obtained with either a monoclonal and a polyclonal antibody radioimmunoassay and their correlations with clinical findings , 1990, Journal of endocrinological investigation.
[55] Inhibition of degradation of insulin by ophthalamic acid and by a bovine pancreatic proteinase inhibitor. , 1979, The Biochemical journal.
[56] T. Buchanan,et al. In vivo kinetics of a covalent growth hormone-binding protein complex. , 1989, Metabolism: clinical and experimental.
[57] F. Carone,et al. Hydrolysis and transport of small peptides by the proximal tubule. , 1980, The American journal of physiology.
[58] L. Boscato,et al. Heterophilic antibodies: a problem for all immunoassays. , 1988, Clinical chemistry.
[59] C. Kluft,et al. Plasminogen activator inhibitors. , 1987, Blood.
[60] T. Kamataki,et al. Effects of hypophysectomy and growth hormone treatment on sex-specific forms of cytochrome P-450 in relation to drug and steroid metabolisms in rat liver microsomes. , 1986, Japanese journal of pharmacology.
[61] J. Jansson,et al. Intravenous growth hormone: growth responses to patterned infusions in hypophysectomized rats. , 1985, The Journal of endocrinology.
[62] D. Drolet,et al. An enzyme-linked immunosorbent assay to study human relaxin in human pregnancy and in pregnant rhesus monkeys. , 1989, The Journal of endocrinology.
[63] Sørensen Jt,et al. Use of a physiologic pharmacokinetic model of glucose homeostasis for assessment of performance requirements for improved insulin therapies. , 1982 .
[64] M. Stolar,et al. A specific growth hormone-binding protein in human plasma: initial characterization. , 1986, The Journal of clinical endocrinology and metabolism.
[65] A. Kossiakoff,et al. Tertiary structure is a principal determinant to protein deamidation. , 1988, Science.
[66] L. Häggroth,et al. Inhibition of the human tissue plasminogen activator in plasma from different species. , 1984, Thrombosis research.
[67] D. Papachristodoulou,et al. The binding and degradation of 125I-labelled insulin by rat kidney brush-border membranes , 1983 .
[68] P. Bugelski,et al. Internalization of Recombinant Tissue-Type Plasminogen Activator by Isolated Rat Hepatocytes is via Coated Pits , 1990, Thrombosis and Haemostasis.
[69] K. Tsukamoto,et al. Effects of Subchronic Treatment with Natural Human Interferons on Antipyrine Clearance and Liver Function in Patients with Chronic Hepatitis , 1990, Journal of clinical pharmacology.
[70] F. Komada,et al. Fate of porcine and human insulin at the subcutaneous injection site. I. Degradation and absorption of insulins in the rat. , 1985, Journal of pharmacobio-dynamics.
[71] T. W. Haeften. Clinical significance of insulin antibodies in insulin-treated diabetic patients. , 1989 .
[72] P. Halban,et al. The preparation of a semisynthetic tritiated insulin with a specific radioactivity of up to 20 Curies per millimole. , 1975, The Biochemical journal.
[73] J. Parsons,et al. Effects of two treatment regimes with synthetic human parathyroid hormone fragment on bone formation and the tissue balance of trabecular bone in greyhounds. , 1983, Endocrinology.
[74] S. Nielsen,et al. Insulin absorption in renal proximal tubules: a quantitative immunocytochemical study. , 1989, Journal of ultrastructure and molecular structure research.
[75] N. White,et al. Diabetes responsive to intravenous but not subcutaneous insulin: effectiveness of aprotinin. , 1981, The New England journal of medicine.
[76] M. Cronin,et al. The pharmacokinetics and pharmacodynamics of a human relaxin in the mouse pubic symphysis bioassay. , 1989, Endocrinology.
[77] V. Bocci. Catabolism of therapeutic proteins and peptides with implications for drug delivery , 1989 .
[78] A C Herington,et al. Identification and characterization of specific binding proteins for growth hormone in normal human sera. , 1986, The Journal of clinical investigation.
[79] A. Doble,et al. Degradation of atrial natriuretic peptides by an enzyme in rat kidney resembling neutral endopeptidase 24.11. , 1988, Biochemical pharmacology.
[80] S. Nielsen,et al. Basolateral tubular handling of insulin in the kidney. , 1988, Contributions to nephrology.
[81] M. Rechler. Insulin-like growth factor binding proteins. , 1993, Vitamins and hormones.
[82] D. Longo,et al. Resistance to recombinant interferon alfa-2a in hairy-cell leukemia associated with neutralizing anti-interferon antibodies. , 1988, The New England journal of medicine.
[83] D. Finbloom. Internalization and degradation of human recombinant interferon-gamma in the human histiocytic lymphoma cell line, U937: relationship to Fc receptor enhancement and antiproliferation. , 1988, Clinical immunology and immunopathology.
[84] C. McMartin,et al. Peptide hormones and their analogues: distribution, clearance from the circulation, and inactivation in vivo. , 1978, Pharmacological reviews.
[85] B. Clarke,et al. Influence of insulin antibodies on pharmacokinetics and bioavailability of recombinant human and highly purified beef insulins in insulin dependent diabetics. , 1985, British medical journal.
[86] A. Bhown. Protein/Peptide Sequence Analysis: Current Methodologies , 1987 .
[87] A. Cerami,et al. Cachectin (Tumor Necrosis Factor) , 1988 .
[88] G. Farrell,et al. Inhibition of antipyrine metabolism by interferon. , 1986, British journal of clinical pharmacology.
[89] D. Shulman,et al. Growth Hormone by Daily Injection in Patients Previously Treated for Growth Hormone Deficiency , 1990, Southern medical journal (Birmingham, Ala. Print).
[90] O. D. de Noord,et al. Effects of alpha-interferon on theophylline pharmacokinetics and metabolism. , 1989, British journal of clinical pharmacology.
[91] C. Crowley,et al. The Influence of Carbohydrate Structure on the Clearance of Recombinant Tissue-Type Plasminogen Activator , 1988, Thrombosis and Haemostasis.
[92] R. Stach,et al. Interaction of nerve growth factor with murine α‐macroglobulin , 1989 .
[93] M. Sporn,et al. Differential inhibition of transforming growth factor beta 1 and beta 2 activity by alpha 2-macroglobulin. , 1990, The Journal of biological chemistry.
[94] J. L. Bailey,et al. Techniques in protein chemistry , 1989 .
[95] D. Carlo,et al. Interferon-induced changes in pharmacokinetics and tumor uptake of 111In-labeled antimelanoma antibody 96.5 in melanoma patients. , 1988, Journal of the National Cancer Institute.
[96] W. Daughaday,et al. Studies on human growth hormone. II. The physiological disposition and metabolic fate of human growth hormone in man. , 1962, The Journal of clinical investigation.
[97] G. Pessina,et al. The role of liver in the catabolism of human alpha- and beta-interferon. , 1982, The Journal of general virology.
[98] W. Kreutner,et al. Potentiation of the hypoglycemic effect of insulin by thiorphan, an enkephalinase inhibitor. , 1984, European journal of pharmacology.
[99] G. Ashwell,et al. Carbohydrate-specific receptors of the liver. , 1982, Annual review of biochemistry.
[100] V. Lee. Enzymatic barriers to peptide and protein absorption. , 1988, Critical reviews in therapeutic drug carrier systems.
[101] A. Varshavsky,et al. In vivo half-life of a protein is a function of its amino-terminal residue. , 1986, Science.
[102] D. Goeddel,et al. Expression of human immune interferon cDNA in E. coli and monkey cells , 1982, Nature.
[103] R. Baughman,et al. Pharmacokinetics and tissue distribution of recombinant human tumor necrosis factor-alpha in mice. , 1988, Drug metabolism and disposition: the biological fate of chemicals.
[104] L. Goodman,et al. The Pharmacological Basis of Therapeutics , 1941 .
[105] B. Beaufrère,et al. Recycling of an amino acid label with prolonged isotope infusion: implications for kinetic studies. , 1985, The American journal of physiology.
[106] D. Clemmons. The Role of Insulin-Like Growth Factor Binding Proteins in Controlling the Expression of IGF Actions , 1989 .
[107] C. McClain,et al. Interleukin-1 (IL-1) depresses cytochrome P450 levels and activities in mice. , 1987, Life sciences.
[108] S. Rogers,et al. Amino acid sequences common to rapidly degraded proteins: the PEST hypothesis. , 1986, Science.
[109] D. Chan,et al. Immunoassay : a practical guide , 1987 .
[110] R. Clark,et al. Growth induced by pulsatile infusion of an amidated fragment of human growth hormone releasing factor in normal and GHRF-deficient rats , 1985, Nature.
[111] G. Singh,et al. Homogeneous interferon from E. coli depresses hepatic cytochrome P-450 and drug biotransformation. , 1982, Biochemical and biophysical research communications.
[112] R. Billings,et al. CELLULAR CATABOLISM OF RECOMBINANT TISSUE-TYPE PLASMINOGEN ACTIVATOR: IDENTIFICATION AND CHARACTERIZATION OF A NOVEL HIGH AFFINITY UPTAKE SYSTEM ON RAT HEPATOCYTES , 1987, Thrombosis and Haemostasis.
[113] T. V. van Berkel,et al. Characterization of the interaction in vivo of tissue-type plasminogen activator with liver cells. , 1988, The Journal of biological chemistry.
[114] B. Sobel,et al. Interactions of tissue-type plasminogen activator with plasma inhibitors and their pharmacologic implications. , 1988, Circulation.
[115] R. Coffey,et al. Hepatic processing of transforming growth factor beta in the rat. Uptake, metabolism, and biliary excretion. , 1987, The Journal of clinical investigation.
[116] P. Matsudaira. A Practical guide to protein and peptide purification for microsequencing , 1989 .
[117] A. Kakinuma,et al. Differential purification by immunoaffinity chromatography of two carboxy-terminal portion-deleted derivatives of recombinant human interferon-gamma from Escherichia coli. , 1987, Journal of interferon research.
[118] John T. Wilson. Alteration of Normal Development of Drug Metabolism by Injection of Growth Hormone , 1970, Nature.
[119] E. Hersh,et al. Modification of human leukocyte interferon pharmacology with a monoclonal antibody. , 1985, Cancer research.
[120] S. Adibi,et al. Specificity and mechanism of influence of amino acid residues on hepatic clearance of oligopeptides. , 1988, The Journal of biological chemistry.
[121] L. Benet,et al. Pharmacokinetics and protein therapeutics , 1990 .
[122] J. Whicher,et al. Electrophoresis and densitometry of serum and urine in the investigation and significance of monoclonal immunoglobulins , 1990, Electrophoresis.
[123] T. Buchanan,et al. The effect of circulating growth hormone-binding protein on metabolic clearance, distribution, and degradation of human growth hormone. , 1987, The Journal of clinical endocrinology and metabolism.
[124] J. Merryweather,et al. Isolation from adult human serum of four insulin-like growth factor (IGF) binding proteins and molecular cloning of one of them that is increased by IGF I administration and in extrapancreatic tumor hypoglycemia. , 1990, The Journal of biological chemistry.
[125] P. Halban,et al. Distribution and metabolism of intravenously injected tritiated insulin in rats. , 1979, Metabolism: clinical and experimental.
[126] J. Koehn,et al. Degradation of atrial natriuretic factor by kidney cortex membranes. Isolation and characterization of the primary proteolytic product. , 1987, The Journal of biological chemistry.
[127] T. Ulich,et al. Effect of IgG Subclasses on In Vivo Bioavailability and Metabolic Fate of Immune-Complexed Insulin in Lewis Rats , 1987, Diabetes.
[128] D. Bier. Intrinsically difficult problems: the kinetics of body proteins and amino acids in man. , 1989, Diabetes/metabolism reviews.
[129] Charles Ward Parker,et al. Radioimmunoassay of biologically active compounds , 1976 .
[130] J. Gauldie,et al. Alpha 2-macroglobulin and serum preferentially counteract the mitoinhibitory effect of transforming growth factor-beta 2 in rat hepatocytes. , 1990, Laboratory investigation; a journal of technical methods and pathology.
[131] M. Binoux,et al. Analysis of serum insulin-like growth factor binding proteins using western blotting: use of the method for titration of the binding proteins and competitive binding studies. , 1986, Analytical biochemistry.
[132] T. Tuvemo. What is the Best Mode of Growth Hormone Administration? , 1989, Acta paediatrica Scandinavica. Supplement.
[133] F. Komada,et al. Pharmaceutical approach to subcutaneous dosage forms of insulin. , 1983, Journal of pharmaceutical sciences.
[134] U. Lewis,et al. Enhancement of the growth promoting activity of human growth hormone. , 1975, Biochemical and biophysical research communications.
[135] B. Howard,et al. Effects of intraperitoneal versus subcutaneous insulin administration on lipoprotein metabolism in type I diabetes. , 1990, Metabolism: clinical and experimental.
[136] P. Halban,et al. The Effect of Aprotinin on the Absorption of Subcutaneously Injected Regular Insulin in Normal Subjects , 1980, Diabetes.
[137] J. Moore,et al. Metabolism, Endocrinology and ImmunologyInfluence of Various Purified Interferons on Effects of Drugs in Mice , 1983 .
[138] V. Bocci. Metabolism of protein anticancer agents. , 1987, Pharmacology & therapeutics.
[139] E. Góth,et al. [Studies on human growth hormone]. , 1963, Orvosi hetilap.
[140] N. LaRusso. Proteins in bile: how they get there and what they do. , 1984, The American journal of physiology.
[141] G. Bolli. The pharmacokinetic basis of insulin therapy in diabetes mellitus. , 1989, Diabetes research and clinical practice.
[142] Deborah L. Higgins,et al. Tissue plasminogen activator: the biochemistry and pharmacology of variants produced by mutagenesis. , 1990, Annual review of pharmacology and toxicology.
[143] F. Bidlingmaier,et al. Circulating antibodies to mouse monoclonal immunoglobulins caused false-positive results in a two-site assay for alpha-fetoprotein. , 1989, Clinical chemistry.
[144] M. Muscettola,et al. The lymphatic route--III. Pharmacokinetics of human natural interferon-beta injected with albumin as a retarder in rabbits. , 1986, General pharmacology.
[145] K. Hall,et al. Growth factors : from genes to clinical application , 1990 .
[146] Ajit K. Thakur,et al. New Trends in Pharmacokinetics , 1991, NATO ASI Series.
[147] W. Hagopian,et al. Hepatic glucagon metabolism. Correlation of hormone processing by isolated canine hepatocytes with glucagon metabolism in man and in the dog. , 1987, The Journal of clinical investigation.
[148] J. Gosling. A decade of development in immunoassay methodology. , 1990, Clinical chemistry.
[149] J. Heersche,et al. Parathyroid hormone stimulates the bone apposition rate independently of its resorptive action: differential effects of intermittent and continuous administration. , 1982, Endocrinology.
[150] R N Bergman,et al. Assessment of insulin sensitivity in vivo. , 1985, Endocrine reviews.
[151] A. Katz,et al. Metabolism of polypeptide hormones by the normal kidney and in uremia. , 1978, Nephron.
[152] E. Goldwasser,et al. Purification of human erythropoietin. , 1977, The Journal of biological chemistry.
[153] J. Playfair,et al. Serum IL-2 inhibitor in mice. I. Increase during infection. , 1985, Immunology.
[154] H. Burger,et al. Metabolic clearance rate of radioiodinated human growth hormone in man. , 1969, The Journal of clinical investigation.